A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS.
Saved in:
| Title: | A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS. |
|---|---|
| Authors: | Tombal, B. (AUTHOR), Smith, M.R. (AUTHOR), Hussain, M. (AUTHOR), Saad, F. (AUTHOR), Fizazi, K. (AUTHOR), Sternberg, C.N. (AUTHOR), Crawford, E.D. (AUTHOR), Kapur, S. (AUTHOR), Zhang, W. (AUTHOR), Ploeger, B. (AUTHOR), Li, R. (AUTHOR), Kuss, I. (AUTHOR), Zieschang, C. (AUTHOR), Wittemer-Rump, S. (AUTHOR), Rezazadeh Kalebasty, A. (AUTHOR) |
| Source: | European Urology. Feb2023:Supplement 1, Vol. 83, pS1709-S1710. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
